Premium
Novel monoclonal antibodies detect elevated levels of the chemokine CCL18/DC‐CK1 in serum and body fluids in pathological conditions
Author(s) -
Van der Voort Robbert,
Kramer Matthijs,
Lindhout Ernst,
Torensma Ruurd,
Eleveld Dagmar,
Van Lieshout Antoine W. T.,
Looman Maaike,
Ruers Theo,
Radstake Timothy R. D. J.,
Figdor Carl G.,
Adema Gosse J.
Publication year - 2005
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1189/jlb.0804435
Subject(s) - ccl18 , chemokine , biology , immunology , microbiology and biotechnology , immune system
CC chemokine ligand 18/dendritic cell‐chemokine 1 (CCL18/DC‐CK1) is a CC chemokine, preferentially expressed by DC, which acts as a chemoattractant for naive T cells and mantle zone B cells. Applying a newly developed CCL18/DC‐CK1 sandwich enzyme‐linked immunosorbent assay, we demonstrate that DC secrete high amounts of CCL18/DC‐CK1 and that this expression can be increased by interleukin‐10. High levels of CCL18/DC‐CK1 were also detected in human serum (average of 88 ng/ml). Moreover, elevated CCL18/DC‐CK1 levels were detected in synovial fluid from rheumatoid arthritis patients and in drain fluid (average of 254 ng/ml and 122 ng/ml, respectively). Immunoprecipitation experiment using anti‐CCL18/DC‐CK1 monoclonal antibodies revealed a protein of 6–7 kDa in serum and drain fluid that was indistinguishable from recombinant CCL18/DC‐CK1 on Western blot and in re‐aggregation assays. The concentration of CCL18/DC‐CK1 found in human serum is in the same order of magnitude as was previously reported to completely inhibit CCL11/eotaxin‐induced CC chemokine receptor 3 (CCR3) activation and consequent migration of eosinophils. CCL18/DC‐CK1 may therefore function as an agonist (for naive T and B cells) and as an antagonist for CCR3‐expressing leukocytes such as eosinophils.